Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

• Main Authors: Javier Cortes (Author), Eric P Winer (Author), Oleg Lipatov (Author), Seock‐Ah Im (Author), Anthony Gonçalves (Author), Eva Muñoz‐Couselo (Author), Keun Seok Lee (Author), Peter Schmid (Author), Kenji Tamura (Author), Laura Testa (Author), Isabell Witzel (Author), Shoichiro Ohtani (Author), Stephanie Hund (Author), Karina Kulangara (Author), Vassiliki Karantza (Author), Jaime A Mejia (Author), Junshui Ma (Author), Petar Jelinic (Author), Lingkang Huang (Author), Scott K Pruitt (Author), Kenneth Emancipator (Author)
• Format: Book
• Published: Wiley, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD‐L1) expression, as quantified by combined positive score (CPS; PD‐L1 expression on both tumour cells and immune cells) in patients with previously treated metastatic triple‐...